Mechanisms of daptomycin resistance in Staphylococcus aureus: Role of the cell membrane and cell wall

Annals of the New York Academy of Sciences

Volumn 1277, Issue 1, 2013, Pages 139-158

  Bayer, Arnold S ^a,b   Schneider, Tanja ^c   Sahl, Hans Georg ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Antibiotic resistance; Daptomycin; Endocarditis; Staphylococcus aureus

Indexed keywords

BACTERIAL PROTEIN; BETA LACTAM; DALFOPRISTIN; DAPTOMYCIN; GENTAMICIN; GLYCEROL DERIVATIVE; LINEZOLID; MPRF PROTEIN; NAFCILLIN; PHOSPHOLIPID; QUINUPRISTIN; SULFAMETHOXAZOLE; TEICHOIC ACID; TELAVANCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; YYCFG PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CELL MEMBRANE POTENTIAL; CHEMICAL STRUCTURE; CROSS RESISTANCE; DEPOLARIZATION; DRUG MECHANISM; DRUG MEGADOSE; GENE FUNCTION; GENE LOCUS; GENE MUTATION; HUMAN; MEMBRANE BINDING; MEMBRANE PERMEABILITY; NONHUMAN; OPERON; PHENOTYPE; PIGMENTATION; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 84872858655     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06819.x     Document Type: Article

References (125)

1. Liu, C., A. Bayer, S.E. Cosgrove, et al 2011. Infectious Diseases Society of America (IDSA). Clinical practice guidelines by the IDSA for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52: e18-e55.
2. Tong, S.Y.C., Luke F. Chen & V.G. Fowler 2012. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance Semin. Immunopatholo. 34: 185-200.
3. Chambers, H.F. & F.R. DeLeo 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7: 629-641.
4. Vancomycin-resistant Staphylococcus aureus-Pennsylvania. 2002. Morb. Mortal Wkly. Rep. 51: 565-567.
5. Liu, C., C.J. Graber, M. Karr, et al 2008. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco 2004-2005. Clin. Infect. Dis. 46: 1637-1646.
6. Howden, B.P., J.K. Davies, P.D. Johnson, et al 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23: 99-139.
7. Lodise, T.P., J. Graves, A. Evans, et al 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52: 3315-3320.
8. Haque, N.Z., L.C. Zuniga, P. Peyrani, et al 2010. Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 138: 1356-1362.
9. Yoon, Y.K., J.Y. Kim & D.W. Park 2010. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 65: 1015-1018.
10. Sakoulas, G., P.A. Moise-Broder, J.J. Schentag, et al 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42: 2398-2402.
11. Hidayat, L.K., D. Hsu, R. Quist, et al 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 66: 2138-2144.
12. Maclayton, D.O., K.J. Suda, K.A. Coval, et al 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Therap. 28: 1208-1216.
13. Neoh, H.M., S. Hori, M. Komatsu, et al 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 6: 13.
14. Soriano, A., F. Marco, J.A. Martínez, et al 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46: 193-200.
15. Musta, A.C., K. Riederer, S. Shemes, et al 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47: 1640-1644.
16. Wang, J.L., J.T. Wang, W.H. Sheng, et al 2010. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect. Dis. 10: 159.
17. Choi, E.Y., J.W. Huh, C.M. Lim, et al 2011. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med. 37: 639-647.
18. Chambers, H.F., L. Basuino, B.A. Diep, et al 2009. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob. Agents Chemother. 53: 1463-1467.
19. Vikram, H.R., N.L. Havill, L.M. Koeth, et al 2005. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J. Clin. Microbiol. 43: 5384-53387.
20. Julian, K., K. Kosowska-Shick, C. Whitener, et al 2007. Characterization of a daptomycin-nonsusceptible, vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51: 3445-3448.
21. Hayden, M.K., K. Rezai, K. Hayes, et al 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43: 5285-5287.
22. Jones, T., M.R. Yeaman, G. Sakoulas, et al 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry and drug binding. Antimicrob. Agents Chemother. 52: 269-278.
23. Murthy, M.H., M.E. Olson, R.E. Wickert, et al 2008. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J. Med. Microbiol. 57: 1036-1038.
24. Fowler, V.G., Jr., H.W. Boucher, G.R. Corey, et al 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355: 653-665.
25. Cunha, B.A. & F.M. Pherez 2009. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus mitral valve acute bacterial endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 28: 831-833.
26. Sharma, M., K. Riederer, P. Chase, et al 2008. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 27: 433-437.
27. Muraih, J.K., A. Pearson, J. Silverman, et al 2011. Oligomerization of daptomycin on membranes. Biochim. Biophys. Acta 1808: 1154-1160.
28. Ho, S.W., D. Jung J.R. Calhoun, et al 2008. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur. Biophys. J. 37: 421-433.
29. Strauss, S.K. 2006. Hancock REW. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758: 1215-1223.
30. Scott, H.R.P., S-B Baek, D. Jung, et al 2007. NMR structure of the antibiotic lipopeptide daptomycin in DHPC micelles. Biochim. Biophys. Acta 1768: 3116-3126.
31. Grunewald, J., S.A. Sieber, M.A. Mahlert, et al 2004. Synthesis and derivatization of daptomycin: a chemoenzymatic route to acidic lipopeptide antibiotics. J. Am. Chem. Soc. 126: 17025-17031.
32. Jung, D., A. Rozek, M. Okon, et al 2004. Structural transitions as determinants of the action of the calcium-dependent antibiotic, daptomycin. Chem. Biol. 11: 949-957.
33. Kopp, F., J. Grunewald, C. Mahlert, et al 2006. Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure-activity relationship of daptomycin and A54145. Biochemistry 45: 10474-10481.
34. Cotroneo, N., R. Harris, N. Perlmutter, et al 2008. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2223-2225.
35. Mascio, T.M., J.D. Adler & J.A. Silverman 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51: 4255-4260.
36. Friedman, L., J. D. Adler & J. A. Silverman 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 2137-2145.
37. Yang, S.J., Y.Q. Xiong, P.M. Dunman, et al 2009. Regulation of mprF in daptomycin- nonsusceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2636-2637.
38. Kaatz, G.W., T.S. Lundstrom & S.M. Seo 2006. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int. J. Antimicrob. Agents 28: 280-287.
39. Patel, D., M. Husain, C. Vidaillac, et al 2011. Mechanisms of in vitro-selected daptomycin non-susceptibility in Staphylococcus aureus. Int. J. Antimicrob. Agents 38: 442-446.
40. Ernst, C.M. & A. Peschel 2011. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol. Microbiol. 80: 290-299.
41. Ernst, C.M., P. Staubitz, N.N. Mishra, et al 2009. The bacterial defensin resistance protein, MprF, consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PloS Pathog. 5: e1000660.
42. Goldmann, A.J., C.M. Ernst, A. Peschel, et al 2011. Multiple peptide resistance factor (MprF)-mediated resistance of Staphylococcus aureus against antimicrobial peptides coincides with a modulated peptide interaction with artificial membranes comprising lysyl-phosphatidylglycerol. J. Biol. Chem. 286: 18692-18700.
43. Kilelee, E., A. Pokorny, M. R. Yeaman, et al 2010. Lysyl-PG attenuates membrane perturbation rather than surface association of the platelet cationic antimicrobial peptide 6W-RP-1 in a model membrane system-implications for daptomycin resistance. Antimicrob. Agents Chemother. 54: 4476-4479.
44. Hachmann, A.-B., E. Sevim, A. Gaballa, et al 2011. Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Antimicrob. Agents Chemother. 55: 4326-4337.
45. Hachmann, A.-B., E.R. Angert & J.D. Helmann 2009. Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrob. Agents Chemother. 53: 1598-1609.
46. Peleg, A.Y., S. Miyakis, D.V. Ward, et al 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PloS One 7: e28316.
47. Muraih, J.K., J. Harris, S.D. Taylor, et al 2012. Characterization of daptomycin oligimerization with perylene excimer fluorescence: stoichiometric binding of phosphatidylglycerol triggers oligomer formation. Bichemica. et. Biophysica. Acta. 1818: 673-678.
48. Rubio, A., M. Conrad, R.J. Haselbeck, et al 2011. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 55: 364-367.
49. Yang S.-J., N.N. Mishra, A. Rubio, et al 2011. The causal role of single nucleotide polymorphisms with the mprF gene of Staphylococcus aureus in daptomycin resistance. 51st ICAAC, Chicago, IL, September 2011.
50. Yang, S.J., B.N. Kreiswirth, G. Sakoulas, et al 2009. Enhanced expression of dltABCD, but not mprF, is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200: 1916-1920.
51. Patel, J.B., L.A. Jevitt, J. Hageman, et al 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42: 1652-1653.
52. Mwangi, M.M., S.W. Wu, Y. Zhou, et al 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Nat. Acad. Sci. USA 104: 9451-9456.
53. Pillai, S.K., H.S. Gold, G. Sakoulas, et al 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in mprF. Antimicrob. Agents Chemother. 51: 2223-2225.
54. Sakoulas, G., J. Adler, C. Thauvin-Eliopoulos, et al 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50: 1581-1585.
55. Cui, L., E. Toninaga, H-M Neoh, et al 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 1079-1082.
56. Mishra, N.N., S.J. Yang, A. Sawa, et al 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of MRSA. Antimicrob. Agents Chemother. 53: 2312-2318.
57. Dhand, A., A.S. Bayer, J. Pogliano, et al 2011. Use of anti-staphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA): role of enhanced daptomycin binding. Clin. Infect. Dis. 53: 158-163.
58. Bayer, A.S., R. Prasad, J. Chandra, et al 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced microbicidal protein is associated with alterations in membrane fluidity. Infect. Immun. 68: 3548-3553.
59. Kupferwasser, L.I., R.A. Skurray, M.H. Brown, et al 1999. Staphylococcus aureus resistance to the cationic peptide, thrombin-induced platelet microbicidal protein-1 is encoded by the multiresistance plasmid pSK1. Antimicrob. Agents Chemother. 43: 2395-2399.
60. Bayer, A.S., L.I. Kupferwasser, M.H. Brown, et al 2006. Low-level Staphylococcus aureus resistance to thrombin-induced platelet microbicidal protein-1 (tPMP-1) in vitro associated with qacA gene carriage is independent of multidrug efflux pump activity. Antimicrob. Agents Chemother. 50: 2448-2454.
61. Mishra, N.N., J. McKinnell, M.R. Yeaman, et al 2011. In vitro cross-resistance of daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates. Antimicrob. Agents Chemother. 55: 4012-4018.
62. Liu, C.I., G.Y. Liu, Y. Song, et al 2008. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319: 1391-1394.
63. Mishra, N.N., G.Y. Liu, M.R. Yeaman, et al 2011. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob. Agents Chemother. 55: 526-531.
64. Holt, D.C., M.T.G. Holden & S.Y.C. Tong 2011. A very early-branching Staphylococcus aureus lineage lacking the carotenoid pigment staphyloxanthin. Genome. Biol. Evol. 3: 881-895.
65. Yeaman, M.R., A.S. Bayer, S-P Koo, et al 1998. Platelet microbicidal proteins differentially permeabilize and depolarize the Staphylococcus aureus cytoplasmic membrane. J. Clin. Invest. 101: 178-187.
66. Yang S.-J., C.C. Nast, N. Mishra, et al 2010. Cell wall thickening is not a universal accompaniment of the daptomycin non-susceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54: 3079-3085.
67. de Leeuw, E., C. Li, P. Zeng, et al 2010. interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett. 584: 1543-1548.
68. Sass, V., U. Pag, A. Tossi, et al 2008. Mode of action of human beta-defensin 3 against Staphylococcus aureus and transcriptional analysis of responses to defensin challenge. Int. J. Med. Microbiol. 298: 619-633.
69. Sass, V., T. Schneider, M. Wilmes, et al 2010. Human beta-defensin 3 inhibits cell wall biosynthesis in staphylococci. Infect. Immun. 78: 2773-2800.
70. Mishra, N.M., A.S. Bayer, P.A. Moise, et al 2012. Reduced susceptibility to host defense cationic peptides and daptomycin co-emerges among methicillin-resistant Staphylococcus aureus (MRSA) in daptomycin-naïve bacteremic patients. J. Infect. Dis. 206: 1160-1167.
71. Saleh-Mghir, A., C. Muller-Serieys, A. Dinh, et al 2011. Adjunctive rifampin is crucial for optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55: 4589-4593.
72. Mishra, N.N., A.S. Bayer, A-C Cremieux, et al Co-evolution of increasing daptomycin MICs and resistance to host defense peptides in rabbits with MRSA prosthetic joint infections. 51st ICAAC, Chicago, IL
73. Bhullar, K., N. Waglechner, A. Pawlowski, et al 2012. Antibiotic resistance is prevalent in an isolated cave microbiome. PloS One 7: 1-11 (e34953).
74. Canepari, P., M. Boaretti, M.M. Lleo & G. Satta 1990. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. 34: 1220-1226.
75. Allen, N.E., J.N. Hobbs & W.E. Alborn 1981. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob. Agents Chemother. 31: 1093-1099.
76. Mengin-Lecreulx, D., N.E. Allen, J.N. Hobbs, et al 1990. Inhibition of peptidoglycan biosynthesis in Bacillus megaterium by daptomycin. FEMS Microbiol. Lett. 57: 245-248.
77. Muthaiyan, A., J.A. Silverman, R.K. Jayaswal, et al 2008. transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob. Agent Chemother. 52: 980-990.
78. Utaida, S., P.M. Dunman, D. Macapagal, et al 2003. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149: 2719-2732.
79. Kuroda, M., H. Kuroda, T. Oshima, et al 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49: 807-821.
80. Wecke, T., D. Zühlke, U. Mäder, et al 2009. Daptomycin versus friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses. Antimicrob. Agents Chemother. 53: 1619-1623.
81. Schneider, T., K. Gries, M. Josten, et al 2009. The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 53: 1610-1618.
82. Song, Y., C.S. Lunde, B.M. Benton, et al 2012. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob. Agents Chemother. 56: 3157-3164.
83. Fischer, A., S.-J. Yang, A.S. Bayer, et al 2011. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. 66: 1696-1711.
84. Bertsche, U., C. Weidenmaier, D. Kuehner, et al 2011. Correlation of daptomycin-resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob. Agents Chemother. 55: 3922-3928.
85. Gutberlet, T., J. Frank, H. Bradaczek, et al 1997. Effect of lipoteichoic acid on thermotropic membrane properties. J. Bacteriol. 179: 2879-2883.
86. Boyle-Vavra, S., M. Jones, B.L. Gourley, et al 2011. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob. Agents Chemother. 55: 2018-2025.
87. McAleese, F., S.W. Wu, K. Sieradzki, et al 2006. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J. Bacteriol. 188: 1120-1133.
88. Balibar, C.J., X. Shen, D. McGuire, et al 2010. cwrA, a gene that specifically responds to cell wall damage in Staphylococcus aureus. Microbiology 156(Pt 5): 1372-83.
89. Balibar, C.J., X. Shen & J. Tao 2009. The mevalonate pathway of Staphylococcus aureus. J. Bacteriol. 191: 851-61.
90. Baltz, R.H. 2009. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13: 144-151. Review.
91. Mohedano, M.L., K. Overweg, A. de la Fuente, et al 2005. Evidence that the essential response regulator YycF in Streptococcus pneumoniae modulates expression of fatty acid biosynthesis genes and alters membrane composition. J. Bacteriol. 187: 2357-2367.
92. Dubrac, S. & T. Msadek 2004. Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J. Bacteriol. 186: 1175-1181.
93. Dubrac, S., I.G. Boneca, O. Poupel, et al 2007. New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in Staphylococcus aureus. J. Bacteriol. 189: 8257-8269.
94. Dubrac, S., P. Bisicchia, K.M. Devine, et al 2008. A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. Mol. Microbiol. 7: 1307-1322.
95. Fukushima, T., H. Szurmant, E.J. Kim, et al 2008. A sensor histidine kinase co-ordinates cell wall architecture with cell division in Bacillus subtilis. Mol. Microbiol. 69: 621-632.
96. Howden, B.P., C.R. McEvoy, D.L. Allen, et al 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 7: e1002359.
97. Jansen, A., M. Türck, C. Szekat, et al 2007. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int. J. Med. Microbiol. 297: 205-215.
98. Delaune, A., O. Poupel, A. Mallet, et al 2011. Peptidoglycan crosslinking relaxation plays an important role in Staphylococcus aureus WalKR-dependent cell viability. PLoS One 28: e17054.
99. Kuroda, H., M. Kuroda, L. Cui, et al 2007. Subinhibitory concentrations of beta-lactam induce haemolytic activity in Staphylococcus aureus through the SaeRS two-component system. FEMS Microbiol. Lett. 268: 98-105.
100. Rogasch, K., V. Rühmling, Pané-Farré, et al 2006. Influence of the two-component system SaeRS on global gene expression in two different Staphylococcus aureus strains. J. Bacteriol. 188: 7742-7758.
101. Steinhuber, A., C. Goerke, M.G. Bayer, et al 2003. Molecular architecture of the regulatory locus sae of Staphylococcus aureus and its impact on expression of virulence factors. J. Bacteriol. 185: 6278-6286.
102. Geiger, T., C. Goerke, M. Mainiero, et al 2008. The virulence regulator Sae of Staphylococcus aureus: promoter activities and response to phagocytosis-related signals. J. Bacteriol. 190: 3419-3428.
103. Mascher, T. 2006. Intramembrane-sensing histidine kinases: a new family of cell envelope stress sensors in Firmicutes bacteria. FEMS Microbiol. Lett. 264: 133-144.
104. Sievers, S., C.M. Ernst, T. Geiger, et al 2010. Changing the phospholipid composition of Staphylococcus aureus causes distinct changes in membrane proteome and membrane-sensory regulators. Proteomics 10: 1685-1693.
105. Kawai, Y., J. Marles-Wright, R.M. Cleverley, et al 2011. A widespread family of bacterial cell wall assembly proteins. EMBO J. 30: 4931-4941.
106. Eberhardt, A., C.N. Hoyland, D. Vollmer, et al 2012. Attachment of capsular polysaccharide to the cell wall in Streptococcus pneumoniae. Microb. Drug Resist. 18: 240-255.
107. Dengler, V., P.S. Meier, R. Heusser, et al 2012. Deletion of hypothetical wall teichoic acid ligases in Staphylococcus aureus activates the cell wall stress response. FEMS Microbiol. Lett. 333: 109-120.
108. Steenbergen, J.N., J.F. Mohr & G.M. Thorne 2009. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J. Antimicrob. Agents Chemother. 64: 1130-1138.
109. Nadrah, K. & F. Strle 2011. Antibiotic combinations with daptomycin for the treatment of Staphylococcus aureus infections. Chemother. Res. Pract. 2011: 619321.
110. Rose, W.E., M.J. Rybak & G.W. Kaatz 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J. Antimicrob. Chemother. 60: 334-340.
111. Rose, W.E., S.N. Leonard & M.J. Rybak 2008. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regiments against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52: 3061-3067.
112. Sakoulas, G., G.M. Eliopoulos, J. Alder, et al 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1714-1718.
113. Lefebvre, M., C. Jacqueline, G. Amador, et al 2010. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Intl. J. Antimicrob. Agents. 36: 542-544.
114. Cirioni, O., F. Mocchegiani, R. Ghiselli, et al 2010. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur. J. Vasc. Endovasc. Surg. 40: 817-822.
115. Lunde, C.S., S.R. Hartouni, J.W. Janc, et al 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor Lipid II. Antimicrob. Agents Chemother. 53: 3375-3383.
116. Krause, K.M., M. Renelli, S. Difuntorum, et al 2008. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob. Agents Chemother. 52: 2647-2652.
117. Steed, M.E., C. Vidaillac & M.J. Rybak 2012. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 56: 955-959.
118. Madrigal, A.G., L. Basuino & H.F. Chambers 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3163-3165.
119. Miro, J.M., C. Garcia-de-la-Maria, Y. Amero, et al 2007. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377.
120. Joson, J., C. Grover, C. Downer, et al 2011. Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure. J. Antimicrob. Chemother. 66: 2186-2188.
121. Marcos, L.A. & B.C. Camins 2010. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob. Agents Chemother. 54: 5376-5378.
122. Vidaillac, C., J. Parra-Ruiz & M.J. Rybak 2011. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn. Microbiol. Infect. Dis. 71: 470-473.
123. Steed, M., C. Vidaillac & M.J. Rybak Evaluation of ceftaroline activity versus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55: 3522-3526.
124. Rand, K.H. & H.J. Houck 2004. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48: 2871-2875.
125. Xiong, Y.Q., W.A. Hady, A.S. Bayer, et al. 2012. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56: 5528-5533.